Skip to main content
Top

2018 | OriginalPaper | Hoofdstuk

17. Neuropsychologische aspecten van neurodegeneratieve aandoeningen

Auteur : Dr. Ben van Cranenburgh

Gepubliceerd in: Neuropsychologie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Neurodegeneratieve aandoeningen zijn doorgaans ongeneeslijke progressieve verzwakkende aandoeningen, op basis van degeneratie of verlies van neuronen of neuronennetwerken. Ze kunnen zich uiten in toenemende motorische, cognitieve, mentale en/of gedragsmatige stoornissen. De meeste neurodegeneratieve aandoeningen hebben een opvallend kernsymptoom, bijvoorbeeld cognitieve achteruitgang bij dementie, spierzwakte bij ALS, rigiditeit en tremor bij de ziekte van Parkinson. Bij vrijwel alle neurodegeneratieve aandoeningen kunnen ook neuropsychologische stoornissen bestaan, enerzijds als subtiel beginsymptoom, anderzijds in het kader van de zich verder ontwikkelende ziekte. Dit hoofdstuk bespreekt van de belangrijkste neurodegeneratieve aandoeningen de diagnostische criteria, de belangrijkste symptomen en verloop, met een accent op de neuropsychologische stoornissen: de dementieën, Parkinson-spectrum-aandoeningen, progressieve supranucleaire parese (PSP), corticobasale degeneratie (CBD), multisysteematrofie (MSA), ziekte van Huntington, multiple sclerose (MS), spinocerebellaire degeneraties, cerebrale amyloïde angiopathieën (CAA) en amyotrofische laterale sclerose (ALS). Het betreft hier een bondig overzicht. Voor uitgebreide informatie wordt verwezen naar tekstboeken klinische neurologie.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Garenfeld W, Piere MAGB van. Psychiatrie, somatische aandoeningen, somatisch-symptoomstoornis en verwante stoornissen. In: Clijsen M, Garenfeld W, Kuipers G, et al, redactie. Leerboek psychiatrie voor verpleegkundigen. Amsterdam: Reed Business Education; 2015. pag. 305–28.CrossRef Garenfeld W, Piere MAGB van. Psychiatrie, somatische aandoeningen, somatisch-symptoomstoornis en verwante stoornissen. In: Clijsen M, Garenfeld W, Kuipers G, et al, redactie. Leerboek psychiatrie voor verpleegkundigen. Amsterdam: Reed Business Education; 2015. pag. 305–28.CrossRef
2.
go back to reference APA. Diagnostic and Statistical Manual of mental disorders. 4th edition, text revised. Washington DC: American Psychiatric Association; 2000. APA. Diagnostic and Statistical Manual of mental disorders. 4th edition, text revised. Washington DC: American Psychiatric Association; 2000.
3.
go back to reference Verdonschot T, Kat M. Neurocognitieve stoornissen. In: Clijsen M, Garenfeld W, Kuipers G, et al., redactie. Leerboek psychiatrie voor verpleegkundigen. Amsterdam: Reed Business Education; 2015. pag. 275–304. Verdonschot T, Kat M. Neurocognitieve stoornissen. In: Clijsen M, Garenfeld W, Kuipers G, et al., redactie. Leerboek psychiatrie voor verpleegkundigen. Amsterdam: Reed Business Education; 2015. pag. 275–304.
4.
go back to reference Stapert S, Diesfeldt H. Ouderen. In: Hendriks M, Kessels R, Gorissen M, et al., redactie. Neuropsychologische diagnostiek. Amsterdam: Boom; 2014. pag. 332–46. Stapert S, Diesfeldt H. Ouderen. In: Hendriks M, Kessels R, Gorissen M, et al., redactie. Neuropsychologische diagnostiek. Amsterdam: Boom; 2014. pag. 332–46.
5.
go back to reference Jost BC, Grossberg GT. The evolution of psychiatric symptoms in alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–81.PubMedCrossRef Jost BC, Grossberg GT. The evolution of psychiatric symptoms in alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–81.PubMedCrossRef
6.
go back to reference Csukly G, Siraly E, Fodor Z, et al. The differentiation of amnestic type MCI from the non-amnestic types by structural MRI. Front Ag Neurosci. 2016;8/52:1–10. Csukly G, Siraly E, Fodor Z, et al. The differentiation of amnestic type MCI from the non-amnestic types by structural MRI. Front Ag Neurosci. 2016;8/52:1–10.
7.
go back to reference Petersen RC, Smith G, Ivnik R, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef Petersen RC, Smith G, Ivnik R, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef
8.
go back to reference Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Ageing-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7(3):270–9.CrossRef Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Ageing-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7(3):270–9.CrossRef
9.
go back to reference Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9.CrossRef Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9.CrossRef
10.
go back to reference Peters ME, Rosenberg PB, Steinberg M, et al. Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study. Am J Geriatr Psychiatry. 2012;20:416–24.PubMedPubMedCentralCrossRef Peters ME, Rosenberg PB, Steinberg M, et al. Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study. Am J Geriatr Psychiatry. 2012;20:416–24.PubMedPubMedCentralCrossRef
11.
go back to reference Feil N. Validation: een nieuwe benadering in de omgang met demente bejaarden. Almere: Versluys; 1989. Feil N. Validation: een nieuwe benadering in de omgang met demente bejaarden. Almere: Versluys; 1989.
12.
go back to reference Flier W van der, Vugt M de. De ziekte van Alzheimer. In: Kessels R, Eling P, Ponds R, et al., redactie. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 423–56. Flier W van der, Vugt M de. De ziekte van Alzheimer. In: Kessels R, Eling P, Ponds R, et al., redactie. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 423–56.
13.
go back to reference NVKG. Richtlijn Diagnostiek en Behandeling van Dementie. Utrecht: Nederlandse Vereniging voor Klinische Geriatrie; 2014. NVKG. Richtlijn Diagnostiek en Behandeling van Dementie. Utrecht: Nederlandse Vereniging voor Klinische Geriatrie; 2014.
14.
go back to reference Dautzenberg PLJ, Schmand B, Vriens MTS, et al. De validiteit van de cognitieve screening-test en de ‘mini-mental state examination’ bij een groep oudere ziekenhuispatiënten. Ned Tijdschr Geneeskd. 1991;135:850–5. Dautzenberg PLJ, Schmand B, Vriens MTS, et al. De validiteit van de cognitieve screening-test en de ‘mini-mental state examination’ bij een groep oudere ziekenhuispatiënten. Ned Tijdschr Geneeskd. 1991;135:850–5.
15.
go back to reference Deelman BG, Maring W, Otten V. De CST: een gestandaardiseerde screeningsmethode voor dementie. In: Schroots JJF, et al., redactie. Cognitieve screenings test. Lisse: Swets Zeitlinger; 1991. pag. 163–70. Deelman BG, Maring W, Otten V. De CST: een gestandaardiseerde screeningsmethode voor dementie. In: Schroots JJF, et al., redactie. Cognitieve screenings test. Lisse: Swets Zeitlinger; 1991. pag. 163–70.
16.
go back to reference Ponds RWHM, Verhey FRJ, Rozendaal N, et al. Dementiescreening:validiteit van de Cognitieve Screeningstest (CST) en de Mini Mental State Examinatuon (MMSE). Tijdschr Gerontol Geriatr. 1992;23:94–9. Ponds RWHM, Verhey FRJ, Rozendaal N, et al. Dementiescreening:validiteit van de Cognitieve Screeningstest (CST) en de Mini Mental State Examinatuon (MMSE). Tijdschr Gerontol Geriatr. 1992;23:94–9.
17.
go back to reference Diesfeldt HFA. Betekenisanalyse van de cognitieve screening test (CST14). Tijdschr Gerontol Geriatr. 1996;27:215–20.PubMed Diesfeldt HFA. Betekenisanalyse van de cognitieve screening test (CST14). Tijdschr Gerontol Geriatr. 1996;27:215–20.PubMed
18.
go back to reference Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98.PubMedCrossRef Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98.PubMedCrossRef
19.
go back to reference Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr So. 2005;53(4):695–99. www.mocatest.org.PubMedCrossRef Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr So. 2005;53(4):695–99. www.​mocatest.​org.PubMedCrossRef
20.
go back to reference Thissen AJ, Bergen van F, Jonghe JF de, et al. Applicability and validity of the Dutch version of the Montreal Cognitive Assessment (MoCA-d) in diagnosing MCI. Tijdschr Gerontol Geriatr. 2010;41(6):231–40. Thissen AJ, Bergen van F, Jonghe JF de, et al. Applicability and validity of the Dutch version of the Montreal Cognitive Assessment (MoCA-d) in diagnosing MCI. Tijdschr Gerontol Geriatr. 2010;41(6):231–40.
21.
go back to reference Wattel L, Achterberg W, redactie. UNO-COG Toolkit – cognitieve meetinstrumenten voor de ouderenzorg- een practice based benadering. Amsterdam: Universitair netwerk ouderenzorg UNO-VUmc; 2010. Wattel L, Achterberg W, redactie. UNO-COG Toolkit – cognitieve meetinstrumenten voor de ouderenzorg- een practice based benadering. Amsterdam: Universitair netwerk ouderenzorg UNO-VUmc; 2010.
22.
go back to reference Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963;185(12):914–9.PubMedCrossRef Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963;185(12):914–9.PubMedCrossRef
23.
go back to reference Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.PubMedCrossRef Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.PubMedCrossRef
24.
go back to reference Verstraten PF, Eekelen CWJ. Gedragsobservatieschaal voor de intramurale psychogeriatrie (GIP). Deventer: Van Loghum Slaterus; 1987. Verstraten PF, Eekelen CWJ. Gedragsobservatieschaal voor de intramurale psychogeriatrie (GIP). Deventer: Van Loghum Slaterus; 1987.
25.
go back to reference Verstraten PF. De GIP: veertien observatieschalen voor psychogeriatrische gedragsproblemen. Tijdschr Gerontol Geriatr. 1988;19(4):147–51.PubMed Verstraten PF. De GIP: veertien observatieschalen voor psychogeriatrische gedragsproblemen. Tijdschr Gerontol Geriatr. 1988;19(4):147–51.PubMed
26.
go back to reference Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14.PubMedCrossRef Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14.PubMedCrossRef
27.
go back to reference Kat MG, Jonghe JF de, Aalten P, et al. Neuropsychiatrische symptomen bij dementie: psychometrische aspecten van de Nederlandse Neuropsychiatric Inventory (NPI). Tijdschr Gerontol Geriatrie. 2002;33:150–5. Kat MG, Jonghe JF de, Aalten P, et al. Neuropsychiatrische symptomen bij dementie: psychometrische aspecten van de Nederlandse Neuropsychiatric Inventory (NPI). Tijdschr Gerontol Geriatrie. 2002;33:150–5.
28.
go back to reference Kaufer D, Cummings JL. NPI-Q. J Clin Neurosci. 2000;12:233–9. (Nederlandse vertaling Jonghe JFM de, Kat MG, Kalisvaart CJ. 2003). Kaufer D, Cummings JL. NPI-Q. J Clin Neurosci. 2000;12:233–9. (Nederlandse vertaling Jonghe JFM de, Kat MG, Kalisvaart CJ. 2003).
29.
go back to reference Jonghe JF de, Kat MG, Reus R de. De validiteit van de gedragsobservatieschaal voor intramurale psychogeriatrie (GIP): een vergelijking met de Bop en NOSIE-30 in een psychiatrische observatiekliniek voor ouderen. Tijdschr Gerontol Geriatr. 1994;25:110–6. Jonghe JF de, Kat MG, Reus R de. De validiteit van de gedragsobservatieschaal voor intramurale psychogeriatrie (GIP): een vergelijking met de Bop en NOSIE-30 in een psychiatrische observatiekliniek voor ouderen. Tijdschr Gerontol Geriatr. 1994;25:110–6.
30.
go back to reference Jonghe JF de, Ooms ME, Ribbe MW. Verkorte gedragsobservatieschaal voor de intramurale psychogeriatrie (GIP-28). Tijdschr Gerontol Geriatr. 1997;28:119–23. Jonghe JF de, Ooms ME, Ribbe MW. Verkorte gedragsobservatieschaal voor de intramurale psychogeriatrie (GIP-28). Tijdschr Gerontol Geriatr. 1997;28:119–23.
31.
go back to reference Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc. 2003;51:657–64.PubMedCrossRef Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc. 2003;51:657–64.PubMedCrossRef
32.
go back to reference Pot AM, Dyck R van, Deeg DJH. Ervaren druk door informele zorg; constructie van een schaal. Tijdschrift Gerontol Geriatr. 1995;26:214–9. Pot AM, Dyck R van, Deeg DJH. Ervaren druk door informele zorg; constructie van een schaal. Tijdschrift Gerontol Geriatr. 1995;26:214–9.
33.
go back to reference Duijnstee M, Guldemond H, Hendriks L. Zorgkompas voor mantelzorgers van ouderen en chronisch zieken: leidraad voor het in kaart brengen van de belasting van zorgende familieleden. Utrecht: NIZW; 2001. Duijnstee M, Guldemond H, Hendriks L. Zorgkompas voor mantelzorgers van ouderen en chronisch zieken: leidraad voor het in kaart brengen van de belasting van zorgende familieleden. Utrecht: NIZW; 2001.
34.
go back to reference APA. Diagnostic and Statistical Manual of mental disorders. 5th edition. Arlington, VA: American Psychiatric Association; 2013. APA. Diagnostic and Statistical Manual of mental disorders. 5th edition. Arlington, VA: American Psychiatric Association; 2013.
35.
36.
go back to reference Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;(134):2456–77. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;(134):2456–77.
38.
go back to reference Raaphorst J, Grupstra HF, Linssen WHJP, et al. Amyotrofische laterale sclerose en frontotemporale dementie. Ned Tijdschr Geneeskd. 2010;154/A631:1–6. Raaphorst J, Grupstra HF, Linssen WHJP, et al. Amyotrofische laterale sclerose en frontotemporale dementie. Ned Tijdschr Geneeskd. 2010;154/A631:1–6.
39.
go back to reference Koning I de, Seelaar H. Frontotemporale dementie. In: Kessels R, Eling P, Ponds R, et al. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 443–56. Koning I de, Seelaar H. Frontotemporale dementie. In: Kessels R, Eling P, Ponds R, et al. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 443–56.
40.
go back to reference MacKenzie IRA, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4.PubMedPubMedCentralCrossRef MacKenzie IRA, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4.PubMedPubMedCentralCrossRef
41.
go back to reference Snowden J., Neary D, Mann D. Frontotemporal lobar degeneration: frontotemporal dementia, progressive aphasia, semantic dementia. New York: Churchill Livingstone; 1996. Snowden J., Neary D, Mann D. Frontotemporal lobar degeneration: frontotemporal dementia, progressive aphasia, semantic dementia. New York: Churchill Livingstone; 1996.
42.
go back to reference Kertesz A, Davidson W, Fox H. Frontal Behavioral Inventory: Diagnostic Criteria for Frontal Lobe Dementia. Can J Neurol Sci. 1997;24:29–36.PubMedCrossRef Kertesz A, Davidson W, Fox H. Frontal Behavioral Inventory: Diagnostic Criteria for Frontal Lobe Dementia. Can J Neurol Sci. 1997;24:29–36.PubMedCrossRef
43.
go back to reference Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–6.PubMedCrossRef Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–6.PubMedCrossRef
44.
go back to reference Loo EH van, Wiebrands C, Laar T van. De ‘Frontal Assessment Battery’ (FAB) voor screening op frontaalkwabpathologie bij neurodegeneratieve ziekten. Tijdschr Neurol Neurochir. 2007;108:115–20. Loo EH van, Wiebrands C, Laar T van. De ‘Frontal Assessment Battery’ (FAB) voor screening op frontaalkwabpathologie bij neurodegeneratieve ziekten. Tijdschr Neurol Neurochir. 2007;108:115–20.
45.
go back to reference Pijnenburg Y, Jansma K, Tol M van, et al. Frontotemporale dementie: best practice – diagnostiek en management. Amsterdam: FTD-Expertgroep; 2012. www.ftdexpertgroep.nl. Pijnenburg Y, Jansma K, Tol M van, et al. Frontotemporale dementie: best practice – diagnostiek en management. Amsterdam: FTD-Expertgroep; 2012. www.​ftdexpertgroep.​nl.
46.
go back to reference Bouma, A. et al. Handboek neuropsychologische diagnostiek. Amsterdam: Pearson; 2012. Bouma, A. et al. Handboek neuropsychologische diagnostiek. Amsterdam: Pearson; 2012.
47.
go back to reference Lezak M. Neuropsychological Assessment. 5th edition. New York: Oxford Un Pr; 2012. Lezak M. Neuropsychological Assessment. 5th edition. New York: Oxford Un Pr; 2012.
48.
go back to reference Bloem BA, Laar T van, Keus SHJ, et al. Multidisciplinaire richtlijn – ziekte van Parkinson. Alphen aan de Rijn: van Zuiden Communications B.V; 2010. Bloem BA, Laar T van, Keus SHJ, et al. Multidisciplinaire richtlijn – ziekte van Parkinson. Alphen aan de Rijn: van Zuiden Communications B.V; 2010.
50.
go back to reference Spielberger S, Poewe W. Overview of parkinsonism and approach to differential diagnosis. In: Burn D, redactie. Oxford textbook of movement disorders. Oxford: Oxford University Press; 2013; pag. 61–72.CrossRef Spielberger S, Poewe W. Overview of parkinsonism and approach to differential diagnosis. In: Burn D, redactie. Oxford textbook of movement disorders. Oxford: Oxford University Press; 2013; pag. 61–72.CrossRef
51.
go back to reference Morgan JC, Mehta SH, Sethi KD. Differential diagnosis. In: Pahwa R, Lyons KE, redactie. Handbook of Parkinson’s disease. Boca Raton, London, New York: CRC Press; 2013.CrossRef Morgan JC, Mehta SH, Sethi KD. Differential diagnosis. In: Pahwa R, Lyons KE, redactie. Handbook of Parkinson’s disease. Boca Raton, London, New York: CRC Press; 2013.CrossRef
52.
go back to reference Defazio G, Tinazzi M, Berardelli A. How pain arises in Parkinson’s disease? Eur J Neurol. 2013;20(12):1517–23.PubMedCrossRef Defazio G, Tinazzi M, Berardelli A. How pain arises in Parkinson’s disease? Eur J Neurol. 2013;20(12):1517–23.PubMedCrossRef
54.
go back to reference Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM Sleep Behavior Disorder: study in 174 patients. PLoS One. 2014;9/2:e89741.PubMedPubMedCentralCrossRef Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM Sleep Behavior Disorder: study in 174 patients. PLoS One. 2014;9/2:e89741.PubMedPubMedCentralCrossRef
55.
go back to reference Postuma RB, Gagnon JF, Vendette M. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.PubMedPubMedCentralCrossRef Postuma RB, Gagnon JF, Vendette M. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.PubMedPubMedCentralCrossRef
56.
go back to reference Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:629–35.CrossRef Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:629–35.CrossRef
57.
go back to reference Weerkamp NJ, Tissingh G, Poels PJ, et al. Nonmotor symptoms in nursing home residents with Parkinson’s disease: prevalence and effect on quality of life. J Am Geriatr Soc. 2013;61/10:1714–21.PubMedCrossRef Weerkamp NJ, Tissingh G, Poels PJ, et al. Nonmotor symptoms in nursing home residents with Parkinson’s disease: prevalence and effect on quality of life. J Am Geriatr Soc. 2013;61/10:1714–21.PubMedCrossRef
58.
go back to reference Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community-based Parkinson’s disease sample. Am J Geriatr Psychiatry. 2012;20/2:123–32.PubMedPubMedCentralCrossRef Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community-based Parkinson’s disease sample. Am J Geriatr Psychiatry. 2012;20/2:123–32.PubMedPubMedCentralCrossRef
59.
go back to reference Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism Relat Disord. 2013;19/8:731–5. Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism Relat Disord. 2013;19/8:731–5.
60.
go back to reference Voss T, Bahr D, Cummings J, et al. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19/3:295–9.CrossRef Voss T, Bahr D, Cummings J, et al. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19/3:295–9.CrossRef
61.
go back to reference Boorsma M, Joling KJ, Frijters DHM, et al. The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homes. Int J Geriatr Psychiatry. 2012;27/7:709–15.PubMedCrossRef Boorsma M, Joling KJ, Frijters DHM, et al. The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homes. Int J Geriatr Psychiatry. 2012;27/7:709–15.PubMedCrossRef
62.
go back to reference Schuurmans MJ, Shortridge-Baggett LM, Duursma SA. The delirium observation screening scale: a screening instrument for delirium. Res Theory Nurs Pract. 2003;17(1):31–50.PubMedCrossRef Schuurmans MJ, Shortridge-Baggett LM, Duursma SA. The delirium observation screening scale: a screening instrument for delirium. Res Theory Nurs Pract. 2003;17(1):31–50.PubMedCrossRef
63.
go back to reference Inouye SK, Dyck CH van, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 Dec 15;113(12):941–8.PubMedCrossRef Inouye SK, Dyck CH van, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 Dec 15;113(12):941–8.PubMedCrossRef
64.
go back to reference NVKG. Richtlijn delier volwassenen en ouderen. Utrecht: Nederlandse Vereniging voor Klinische Geriatrie; 2013. www.nvkg.nl. NVKG. Richtlijn delier volwassenen en ouderen. Utrecht: Nederlandse Vereniging voor Klinische Geriatrie; 2013. www.​nvkg.​nl.
65.
go back to reference Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014 Jan 28;82(4):308–16.PubMedCrossRef Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014 Jan 28;82(4):308–16.PubMedCrossRef
66.
67.
go back to reference Aarsland A, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937–41.PubMedCrossRef Aarsland A, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937–41.PubMedCrossRef
68.
go back to reference Buter TC, Hout A van den, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008(70/13):1017–22.PubMedCrossRef Buter TC, Hout A van den, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008(70/13):1017–22.PubMedCrossRef
69.
go back to reference Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;(23/6):837–44.PubMedCrossRef Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;(23/6):837–44.PubMedCrossRef
70.
go back to reference Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55/3:181–4.CrossRef Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55/3:181–4.CrossRef
71.
go back to reference Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007 Sep 15;22(12):1689–707.PubMedCrossRef Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007 Sep 15;22(12):1689–707.PubMedCrossRef
72.
go back to reference Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314–24.PubMedCrossRef Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314–24.PubMedCrossRef
73.
go back to reference McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies – Fourth consensus report of the DLB Consortium. Neurology 2017;89:88–100. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies – Fourth consensus report of the DLB Consortium. Neurology 2017;89:88–100.
74.
go back to reference Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–59.PubMedCrossRef Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–59.PubMedCrossRef
75.
go back to reference Litvan I, Agid Y, Calne D, et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1–9.PubMedCrossRef Litvan I, Agid Y, Calne D, et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1–9.PubMedCrossRef
76.
go back to reference Williams DR, Silva R de, Paviuor DC. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005;128:1247–58.PubMedCrossRef Williams DR, Silva R de, Paviuor DC. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005;128:1247–58.PubMedCrossRef
77.
go back to reference Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–64. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–64.
78.
go back to reference Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393–4.PubMedCrossRef Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393–4.PubMedCrossRef
79.
go back to reference Stroop J. Studies of interference in serial verbal reaction. J Experiment Psychol. 1935;18:643–62.CrossRef Stroop J. Studies of interference in serial verbal reaction. J Experiment Psychol. 1935;18:643–62.CrossRef
80.
81.
go back to reference Luzzi S, Fabi K, Pesallaccia M, et al. Applause sign: is it really specific for Parkinsonian disorders? Evidence from cortical dementias. J Neurol Neurosurg Psychiatry. 2011;82(8):830–3.CrossRef Luzzi S, Fabi K, Pesallaccia M, et al. Applause sign: is it really specific for Parkinsonian disorders? Evidence from cortical dementias. J Neurol Neurosurg Psychiatry. 2011;82(8):830–3.CrossRef
82.
go back to reference Wu LJ, Sitburana O, Davidson A, et al. Applause sign in Parkinsonian disorders and Huntington’s disease. Mov Disord. 2008;23(16):2307–11.PubMedCrossRef Wu LJ, Sitburana O, Davidson A, et al. Applause sign in Parkinsonian disorders and Huntington’s disease. Mov Disord. 2008;23(16):2307–11.PubMedCrossRef
83.
go back to reference Schmand B, Groenink SC, Dungen vd M. Letterfluency: psychometrische eigenschappen en Nederlandse normen. Tijdschr Gerontol Geriatr. 2008;39/2:65–77. Schmand B, Groenink SC, Dungen vd M. Letterfluency: psychometrische eigenschappen en Nederlandse normen. Tijdschr Gerontol Geriatr. 2008;39/2:65–77.
84.
go back to reference Mattis S. Dementia rating scale; professional manual. Odessa, Fl: Psychological Assessment Resources Inc.; 1988. Mattis S. Dementia rating scale; professional manual. Odessa, Fl: Psychological Assessment Resources Inc.; 1988.
85.
go back to reference Krishnan S, Mathuranath PS, Sarma S, et al. Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson’s disease. Neurol India 2006;54/3:268–72. Krishnan S, Mathuranath PS, Sarma S, et al. Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson’s disease. Neurol India 2006;54/3:268–72.
86.
go back to reference Stamelou M, Diehl-Schmid J, Hapfelmeier A, et al. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism Relat Disord. 2015;21/10:1264–8.CrossRef Stamelou M, Diehl-Schmid J, Hapfelmeier A, et al. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism Relat Disord. 2015;21/10:1264–8.CrossRef
88.
go back to reference Masellis M. Corticobasal syndrome: clinical, neuropsychological, imaging, genetic and pathological features. PhD thesis. Toronto: University of Toronto; 2012. Masellis M. Corticobasal syndrome: clinical, neuropsychological, imaging, genetic and pathological features. PhD thesis. Toronto: University of Toronto; 2012.
89.
go back to reference Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40:1203–12.PubMedCrossRef Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40:1203–12.PubMedCrossRef
90.
go back to reference Rana AQ, Ansari H, Siddiqui I. The relationship between arm dystonia in corticobasal degeneration and handedness. J Clin Neurosci. 2012;19:1134–6.PubMedCrossRef Rana AQ, Ansari H, Siddiqui I. The relationship between arm dystonia in corticobasal degeneration and handedness. J Clin Neurosci. 2012;19:1134–6.PubMedCrossRef
91.
go back to reference Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45:1477–83.PubMedCrossRef Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45:1477–83.PubMedCrossRef
92.
go back to reference Dickson DW, Bergeron C, Chin SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61/11:935–46.CrossRef Dickson DW, Bergeron C, Chin SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61/11:935–46.CrossRef
93.
go back to reference Bürger K, Arzberger T, Stephan J, et al. Pathomechanismen und klinische Aspekte der frontotemporalen Lobärdegeneration. Nervenarzt. 2016;88:163–72.CrossRef Bürger K, Arzberger T, Stephan J, et al. Pathomechanismen und klinische Aspekte der frontotemporalen Lobärdegeneration. Nervenarzt. 2016;88:163–72.CrossRef
94.
go back to reference Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077–81.PubMedCrossRef Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077–81.PubMedCrossRef
95.
go back to reference Siri C, Duerr S, Canesi M, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm. 2013;120:613–8.PubMedCrossRef Siri C, Duerr S, Canesi M, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm. 2013;120:613–8.PubMedCrossRef
96.
go back to reference Ceponiene R, Edland SD, Reid TN, et al. Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. Cogen Psychol. 2016;3:1–10. Ceponiene R, Edland SD, Reid TN, et al. Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. Cogen Psychol. 2016;3:1–10.
97.
go back to reference Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71/9:670–6. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71/9:670–6.
98.
go back to reference Brown RG, Lacomblez L, Landwehrmeyer BG, et al. NNIPPS study group. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010;133(Pt 8):2382–93.PubMedCrossRef Brown RG, Lacomblez L, Landwehrmeyer BG, et al. NNIPPS study group. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010;133(Pt 8):2382–93.PubMedCrossRef
99.
go back to reference Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy; A position statement by the Neuropsychology Task Force of the MDS multiple system atrophy (MODIMSA) study group. Mov Disord. 2014;29(7):857–67.PubMedPubMedCentralCrossRef Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy; A position statement by the Neuropsychology Task Force of the MDS multiple system atrophy (MODIMSA) study group. Mov Disord. 2014;29(7):857–67.PubMedPubMedCentralCrossRef
100.
go back to reference Foster NL, Wilhelmsen K, Sima AA, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference participants. Ann Neurol. 1997;41(6):706–15.PubMedCrossRef Foster NL, Wilhelmsen K, Sima AA, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference participants. Ann Neurol. 1997;41(6):706–15.PubMedCrossRef
101.
102.
go back to reference Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393(6686):702–5. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393(6686):702–5.
103.
go back to reference Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442(7105):916–9. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442(7105):916–9.
104.
105.
go back to reference Seneci P. Molecular targets in protein misfolding and neurodegenerative disease. Amsterdam: Academic Press/Elsevier; 2015. Seneci P. Molecular targets in protein misfolding and neurodegenerative disease. Amsterdam: Academic Press/Elsevier; 2015.
106.
go back to reference Simoes R, Litvan I. Tauopathies. In: Kompolitit K, Verhagen Metman L, redactie. Movement disorders – vol. I. Amsterdam, etc.: Elsevier; 2010. pag. 219–25.CrossRef Simoes R, Litvan I. Tauopathies. In: Kompolitit K, Verhagen Metman L, redactie. Movement disorders – vol. I. Amsterdam, etc.: Elsevier; 2010. pag. 219–25.CrossRef
107.
go back to reference Kuzuhara S, Kokubo Y. Amyotrophic lateral sclerosis – parkinsonism – dementia complex in the Kii peninsula of Japan (Muro disease); a review on recent research and new concept. Kuzuhara S, Kokubo Y. Amyotrophic lateral sclerosis – parkinsonism – dementia complex in the Kii peninsula of Japan (Muro disease); a review on recent research and new concept.
108.
go back to reference Kokubo Y. Diagnostic criteria for amyotrophic lateral sclerosis/Parkinsonism-dementia complex in the Kii Peninsula, Japan. Brain Nerve. 2015;67/7:961–67. (Abstract in English). Kokubo Y. Diagnostic criteria for amyotrophic lateral sclerosis/Parkinsonism-dementia complex in the Kii Peninsula, Japan. Brain Nerve. 2015;67/7:961–67. (Abstract in English).
109.
go back to reference Perl DP, Hof PR, Steele JC, et al. Neuropathologic studies of a pure dementing syndrome (Marianas dementia) among the inhabitants of Guam, a form of ALS/parkinsonism dementia complex. Brain Pathol. 1994;4:529. Geciteerd in: Larner AJ. Neuropsychological neurology: the neurocognitive impairments of neurological disorders. Cambridge: Cambridge University Press; 2013. Perl DP, Hof PR, Steele JC, et al. Neuropathologic studies of a pure dementing syndrome (Marianas dementia) among the inhabitants of Guam, a form of ALS/parkinsonism dementia complex. Brain Pathol. 1994;4:529. Geciteerd in: Larner AJ. Neuropsychological neurology: the neurocognitive impairments of neurological disorders. Cambridge: Cambridge University Press; 2013.
110.
go back to reference Shindo A, Ueda Y, Kuzuhara S, et al. Neuropsychological study of lateral sclerosis and parkinsonism-dementia complex in Kii pensinsula, Japan. BMC Neurol. 2014;14/151:1–8. Shindo A, Ueda Y, Kuzuhara S, et al. Neuropsychological study of lateral sclerosis and parkinsonism-dementia complex in Kii pensinsula, Japan. BMC Neurol. 2014;14/151:1–8.
111.
go back to reference Peng Q, Wu B, Jiang M. Characterization of behavioral, neuropathological, brain metabolic and key molecular changes in zQ175 knock-in mouse model of Huntington’s disease. PLoS One. 2016;11(2):e0148839.PubMedPubMedCentralCrossRef Peng Q, Wu B, Jiang M. Characterization of behavioral, neuropathological, brain metabolic and key molecular changes in zQ175 knock-in mouse model of Huntington’s disease. PLoS One. 2016;11(2):e0148839.PubMedPubMedCentralCrossRef
112.
go back to reference Quarrell OWJ, Rigby AS, Barron L, et al. Reduced penetrance alleles for Huntington’s disease: a multi‐centre direct observational study. J Med Genet. 2007;44(3):e68.CrossRef Quarrell OWJ, Rigby AS, Barron L, et al. Reduced penetrance alleles for Huntington’s disease: a multi‐centre direct observational study. J Med Genet. 2007;44(3):e68.CrossRef
113.
go back to reference Kay C, Collins JA, Miedzybrozdka Z, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology 2016;87(3):282–8.PubMedPubMedCentralCrossRef Kay C, Collins JA, Miedzybrozdka Z, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology 2016;87(3):282–8.PubMedPubMedCentralCrossRef
114.
go back to reference Estrada-Sanchez AM, Rebec GV. Role of cerebral cortex in the neuropathology of Huntington’s disease. Front Neural Circuits. 2013;7(19):1–9. Estrada-Sanchez AM, Rebec GV. Role of cerebral cortex in the neuropathology of Huntington’s disease. Front Neural Circuits. 2013;7(19):1–9.
115.
go back to reference VSOP (Vereniging Samenwerkende Ouder- en Patiëntenorganisaties), VvH (Vereniging van Huntington), NHG (Nederlands Huisartsen Genootschap). Informatie voor de huisarts over de ziekte van Huntington. Soest:VSOP; 2010. VSOP (Vereniging Samenwerkende Ouder- en Patiëntenorganisaties), VvH (Vereniging van Huntington), NHG (Nederlands Huisartsen Genootschap). Informatie voor de huisarts over de ziekte van Huntington. Soest:VSOP; 2010.
116.
go back to reference Arts NJM, Naarding P. Neuropsychiatrische aspecten van de ziekte van Huntington. Patient Care (Neuropsychiatr Gedragsneurolog). 2005;32(aug):157–65. Arts NJM, Naarding P. Neuropsychiatrische aspecten van de ziekte van Huntington. Patient Care (Neuropsychiatr Gedragsneurolog). 2005;32(aug):157–65.
117.
go back to reference Herben-Dekker M, Jurgens C, Middelkoop H. De ziekte van Huntington. In: Kessels R, Eling P, Ponds R, et al. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 473–84. Herben-Dekker M, Jurgens C, Middelkoop H. De ziekte van Huntington. In: Kessels R, Eling P, Ponds R, et al. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 473–84.
118.
go back to reference Aziz NA, Burg JM van der, Landwehrmeyer GB. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008;4(71/19):1506–13. Aziz NA, Burg JM van der, Landwehrmeyer GB. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008;4(71/19):1506–13.
119.
go back to reference Huntington Study Group. The unified Huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996;11:136–42. Huntington Study Group. The unified Huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996;11:136–42.
120.
go back to reference Bylsma FW, Rothlind J, Hall MR, et al. Assessment of adaptive functioning in huntington’s disease. Mov Disord. 1993;8/2:183–90.PubMedCrossRef Bylsma FW, Rothlind J, Hall MR, et al. Assessment of adaptive functioning in huntington’s disease. Mov Disord. 1993;8/2:183–90.PubMedCrossRef
121.
go back to reference Kingma EM, Duijn E van, Timman R, et al. Behavioural problems in Huntington’s disease using the problem behaviours assessment. Gen Hosp Psychiatry. 2008;30:155–61.PubMedCrossRef Kingma EM, Duijn E van, Timman R, et al. Behavioural problems in Huntington’s disease using the problem behaviours assessment. Gen Hosp Psychiatry. 2008;30:155–61.PubMedCrossRef
122.
go back to reference Podbielska M, Banik NL, Kurowska E, et al. Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci. 2013 Aug 28;3(3):1282–324.PubMedPubMedCentralCrossRef Podbielska M, Banik NL, Kurowska E, et al. Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci. 2013 Aug 28;3(3):1282–324.PubMedPubMedCentralCrossRef
123.
go back to reference Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis, the 2013 revisions. Neurology 2014;83/3:278–86. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis, the 2013 revisions. Neurology 2014;83/3:278–86.
124.
125.
go back to reference Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2015;4(5):281–8.PubMedCrossRef Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2015;4(5):281–8.PubMedCrossRef
126.
go back to reference Tintoré M, Rovira A, Río J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;25/70:1079–83.PubMedCrossRef Tintoré M, Rovira A, Río J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;25/70:1079–83.PubMedCrossRef
128.
go back to reference Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387–94.PubMedCrossRef Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387–94.PubMedCrossRef
129.
go back to reference Popescu BFGh, Pirko I, Lucchinettie CF, et al. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19/4:901–21.PubMedPubMedCentral Popescu BFGh, Pirko I, Lucchinettie CF, et al. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19/4:901–21.PubMedPubMedCentral
130.
go back to reference Pender MP. CD8+T-cell Deficiency, Epstein-Barr virus infection, vitamin D deficiency and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis. 2012;Article ID 189096:1–12.CrossRef Pender MP. CD8+T-cell Deficiency, Epstein-Barr virus infection, vitamin D deficiency and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis. 2012;Article ID 189096:1–12.CrossRef
131.
go back to reference Cook SD. Handbook of multiple sclerosis. New York/Basel: Marcel Dekker; 2005. Cook SD. Handbook of multiple sclerosis. New York/Basel: Marcel Dekker; 2005.
132.
go back to reference Kroon J de, Groot V de. Richtlijn multiple sclerose. Ned Tijschr Revalidatiegeneeskd. 2014;6:300–2. Kroon J de, Groot V de. Richtlijn multiple sclerose. Ned Tijschr Revalidatiegeneeskd. 2014;6:300–2.
133.
go back to reference Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–57.PubMedPubMedCentralCrossRef Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–57.PubMedPubMedCentralCrossRef
135.
go back to reference Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69/2:292–302.PubMedPubMedCentralCrossRef Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69/2:292–302.PubMedPubMedCentralCrossRef
136.
go back to reference Algahtani H, Shirah B. Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017;14:72–9.PubMedCrossRef Algahtani H, Shirah B. Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017;14:72–9.PubMedCrossRef
137.
go back to reference Rao SM, Cognitive function study group. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. New York: National Multiple Sclerosis Society; 1990. Rao SM, Cognitive function study group. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. New York: National Multiple Sclerosis Society; 1990.
138.
go back to reference Benedict R, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12:549–58. Benedict R, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12:549–58.
139.
go back to reference Schmahmann JD. An emerging concept: the cerebellar contribution to higher function. Archiv Neurol. 1991;48:1178–87.CrossRef Schmahmann JD. An emerging concept: the cerebellar contribution to higher function. Archiv Neurol. 1991;48:1178–87.CrossRef
140.
go back to reference Schmahmann JD. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatr Clin Neurosci. 2004;16:367–78.CrossRef Schmahmann JD. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatr Clin Neurosci. 2004;16:367–78.CrossRef
141.
go back to reference Buckner RL. The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging. Neuron. 2013;80(3):807–15.PubMedCrossRef Buckner RL. The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging. Neuron. 2013;80(3):807–15.PubMedCrossRef
142.
go back to reference Keage HAD, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9(3):1–8. Keage HAD, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9(3):1–8.
143.
144.
go back to reference Mehndiratta P, Manjila S, Ostergard T, et al. Cerebral amyloid angiopathy-associated intracerebral hemorrhage: pathology and management. Neurosurg Focus. 2012;32(4):E7. Mehndiratta P, Manjila S, Ostergard T, et al. Cerebral amyloid angiopathy-associated intracerebral hemorrhage: pathology and management. Neurosurg Focus. 2012;32(4):E7.
145.
go back to reference Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patient’s with Alzheimer’s disease: the CERAD experience Part XV. Neurology 1996;46(6):1592–6.PubMedCrossRef Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patient’s with Alzheimer’s disease: the CERAD experience Part XV. Neurology 1996;46(6):1592–6.PubMedCrossRef
146.
go back to reference Fernandez-Madrid I, Levy E, Marder K, Frangione B. Codon 618 variant of Alzheimer amyloid gene associated with inherited cerebral hemorrhage. Ann Neurol. 1991;30:730–3.PubMedCrossRef Fernandez-Madrid I, Levy E, Marder K, Frangione B. Codon 618 variant of Alzheimer amyloid gene associated with inherited cerebral hemorrhage. Ann Neurol. 1991;30:730–3.PubMedCrossRef
147.
go back to reference Panegyres PK, Kwok JB, Schofield PR, et al. A Western Australian kindred with Dutch cerebral amyloid angiopathy. J Neurol Sci. 2005;239(1):75–80.PubMedCrossRef Panegyres PK, Kwok JB, Schofield PR, et al. A Western Australian kindred with Dutch cerebral amyloid angiopathy. J Neurol Sci. 2005;239(1):75–80.PubMedCrossRef
148.
go back to reference Bornebroek M, Westendorp RGJ, Haan J, et al. Mortality from hereditary cerebral haemorrhage with amyloidosis—Dutch type. The impact of sex, parental transmission and year of birth. Brain 1997;120:2243–9.PubMedCrossRef Bornebroek M, Westendorp RGJ, Haan J, et al. Mortality from hereditary cerebral haemorrhage with amyloidosis—Dutch type. The impact of sex, parental transmission and year of birth. Brain 1997;120:2243–9.PubMedCrossRef
149.
go back to reference Etten ES van, Gurol ME, Grond J van der, et al. Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology 2016;87:1482–7.PubMedPubMedCentralCrossRef Etten ES van, Gurol ME, Grond J van der, et al. Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology 2016;87:1482–7.PubMedPubMedCentralCrossRef
150.
go back to reference Wattendorf AR, Frangione B, Luyendijk W, et al. Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D): clinicopathological studies. J Neurol Neurosurg Psychiatry. 1995;58:699–705. Wattendorf AR, Frangione B, Luyendijk W, et al. Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D): clinicopathological studies. J Neurol Neurosurg Psychiatry. 1995;58:699–705.
154.
go back to reference Matthews FE, Brayne C, Lowe J, et al. Epidemiological pathology of dementia: attributable risks at death in the medical research council cognitive function and ageing study. Plos Med. 2009;6(11)/e1000180:1–15.PubMedPubMedCentralCrossRef Matthews FE, Brayne C, Lowe J, et al. Epidemiological pathology of dementia: attributable risks at death in the medical research council cognitive function and ageing study. Plos Med. 2009;6(11)/e1000180:1–15.PubMedPubMedCentralCrossRef
155.
go back to reference Bornebroek M, Haan J, Bakker E, et al. Clinical and genetic aspects of hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D). In: Verbeek MM, Waal RM de, Vinters HV, redactie. Cerebral amyloid angiopathy in alzheimer’s disease and related disorders. Dordrecht: Springer Science and Business Media BV; 2000. pag. 103–119. Bornebroek M, Haan J, Bakker E, et al. Clinical and genetic aspects of hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D). In: Verbeek MM, Waal RM de, Vinters HV, redactie. Cerebral amyloid angiopathy in alzheimer’s disease and related disorders. Dordrecht: Springer Science and Business Media BV; 2000. pag. 103–119.
156.
go back to reference Haan J, Lanser JB, Zijderveld I, et al. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Arch Neurol. 1990;47(9):965–7.PubMedCrossRef Haan J, Lanser JB, Zijderveld I, et al. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Arch Neurol. 1990;47(9):965–7.PubMedCrossRef
157.
go back to reference WHO. World health Organisation. Internationale statistische classificatie van ziekten en met gezondheid verband houdende problemen – 10e revisie. (ICD-10). Genève: WHO; 1999. WHO. World health Organisation. Internationale statistische classificatie van ziekten en met gezondheid verband houdende problemen – 10e revisie. (ICD-10). Genève: WHO; 1999.
160.
go back to reference Berg L van den, Berg JP van den, Goeijen JC de, et al. Amyotrofe lateraalsclerose – Landelijke richtlijn 2.0. Utrecht: Integraal Kankercentrum Nederland; 2010. Berg L van den, Berg JP van den, Goeijen JC de, et al. Amyotrofe lateraalsclerose – Landelijke richtlijn 2.0. Utrecht: Integraal Kankercentrum Nederland; 2010.
161.
go back to reference Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6/171:1–23. Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6/171:1–23.
162.
go back to reference Longinetti E, Mariosa D, Larsson H, et al. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis. Neurology 2017;89(6):578–85.PubMedPubMedCentralCrossRef Longinetti E, Mariosa D, Larsson H, et al. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis. Neurology 2017;89(6):578–85.PubMedPubMedCentralCrossRef
163.
go back to reference Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994–1003.PubMedCrossRef Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994–1003.PubMedCrossRef
164.
go back to reference Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(3):131–46.PubMedCrossRef Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(3):131–46.PubMedCrossRef
165.
go back to reference Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3–4):153–74.PubMedCrossRef Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3–4):153–74.PubMedCrossRef
166.
go back to reference Brooks BR, Miller RG, Swash M, et al., for the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. ALS Other Motor Neuron disord. 2000;1:293–9. Brooks BR, Miller RG, Swash M, et al., for the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. ALS Other Motor Neuron disord. 2000;1:293–9.
167.
go back to reference Schelhaas J, Veldink J. Diagnostiek en differntiaal diagnose. In: Berg L van den, Creemers H, Goeijen N de, et al. Zakboekje ALS – amyotrofe lateraal sclerose. Diagnostiek en behandeling – 5 jaar ALS centrum. Utrecht: ALS Centrum Nederland – UMC Utrecht; 2013. Schelhaas J, Veldink J. Diagnostiek en differntiaal diagnose. In: Berg L van den, Creemers H, Goeijen N de, et al. Zakboekje ALS – amyotrofe lateraal sclerose. Diagnostiek en behandeling – 5 jaar ALS centrum. Utrecht: ALS Centrum Nederland – UMC Utrecht; 2013.
168.
go back to reference Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. Amyotrop Lateral Scler Frontotemporal Degener. 2014;15:9–14.PubMedCrossRef Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. Amyotrop Lateral Scler Frontotemporal Degener. 2014;15:9–14.PubMedCrossRef
169.
go back to reference Creemers H, Morée S de, Veldink JH, et al. Factors related to caregiver strain in ALS: a longitudinal study. J Neurol Neurosurg Psychiatry. 2016;87(7):775–81.CrossRef Creemers H, Morée S de, Veldink JH, et al. Factors related to caregiver strain in ALS: a longitudinal study. J Neurol Neurosurg Psychiatry. 2016;87(7):775–81.CrossRef
Metagegevens
Titel
Neuropsychologische aspecten van neurodegeneratieve aandoeningen
Auteur
Dr. Ben van Cranenburgh
Copyright
2018
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2074-5_17